SUNY Downstate spinout Concarlo is working on tests to establish the suitability of breast cancer patients for a therapy known as CDK4 inhibitor treatment.

Qubis has backed Causeway's bid to create a nanochip-powered sensor that would help prevent ineffective antibiotic prescriptions.

Boston Scientific has bought Emcision, a spinout from Imperial College London that is developing a range of surgical instruments.

The cancer immunotherapy developer, backed by Stanford University, has closed the offering after the underwriters bought another $18m of shares.

Depression therapy developer Navitor, which counts EMS, Sanofi, Johnson & Johnson and GlaxoSmithKline as investors, has raised $11.3m of an expected $25m round.

The cancer immunotherapy developer, backed by GV, Celgene, Novartis and Taiho Ventures, has closed the offering after the underwriters bought another $18m of shares.

SoftBank Ventures led the drug discovery platform developer's series A round, participating together with OS Fund and Andreessen Horowitz's Bio Fund.

The Illumina-backed DNA and RNA sequencer provider raised the funding from investors including GIC, Hostplus and China Construction Bank.

The Aptus Therapeutics-backed neurodegenerative disorder drug developer has filed for an $80.5m initial public offering on Nasdaq after raising roughly $30m in VC funding.

The Lund University spinout, which is working on diagnostics technology for applications in oncology, will use the proceeds to pursue a recruitment drive.